IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
AstraZeneca's IMFINZI® (durvalumab) combined with chemotherapy shows significant improvement in event-free survival and overall survival for muscle-invasive bladder cancer (MIBC) in the NIAGARA Phase III trial. This trial demonstrated a notable reduction in disease recurrence and progression. Patients were treated with IMFINZI pre- and post-surgery, achieving better outcomes compared to chemotherapy alone. Approximately 117,000 MIBC patients are treated annually with standard care, which often leads to high recurrence rates. The IMFINZI regimen, well-tolerated with no new safety concerns, potentially transforms the standard of care for MIBC. Data will be presented at an upcoming medical meeting.
- IMFINZI combined with chemotherapy significantly improves event-free survival and overall survival for MIBC patients.
- IMFINZI regimen shows a notable reduction in disease recurrence and progression.
- IMFINZI was well-tolerated with no new safety concerns.
- The trial supports the strategy to move immunotherapy to early-stage cancer treatment.
- Standard care for MIBC still results in high recurrence rates despite neoadjuvant chemotherapy and radical cystectomy.
The results of the NIAGARA Phase III trial for IMFINZI® (durvalumab) in treating muscle-invasive bladder cancer (MIBC) are promising. The improvement in event-free survival (EFS) and overall survival (OS) indicates that adding IMFINZI to chemotherapy before surgery and continuing as monotherapy after, could significantly enhance patient outcomes.
MIBC represents a challenging clinical scenario. Presently, the standard treatment involves neoadjuvant chemotherapy followed by radical cystectomy, but recurrence rates remain high. The data suggesting that IMFINZI can extend the patient's life and reduce recurrence or progression are noteworthy. This could lead to a shift in the treatment paradigm for MIBC, providing an additional layer of defense against the disease returning post-surgery.
Importantly, the safety profile of IMFINZI showed no new safety concerns and it didn't increase discontinuation rates due to adverse events, suggesting it could be well-integrated into current treatment protocols without compromising patient safety or surgical outcomes.
For investors, the implications are significant. If IMFINZI receives regulatory approval for this new application, it could expand its market significantly, addressing the unmet needs of a substantial patient population with MIBC.
From a financial perspective, the positive results from the NIAGARA Phase III trial could have multiple impacts on AstraZeneca’s financial health. First and foremost, the successful demonstration of improved event-free survival (EFS) and overall survival (OS) could lead to regulatory approvals, unlocking new revenue streams. The market for muscle-invasive bladder cancer (MIBC) treatments is considerable, with around 117,000 patients treated annually under the current standard of care.
The lack of new safety concerns and the compatibility with existing chemotherapy protocols are significant. They suggest a seamless integration of IMFINZI into the treatment landscape, which could expedite its adoption and commercialization, minimizing the risk associated with adverse events negatively impacting its market performance.
AstraZeneca's strategy to move immunotherapy to earlier stages of cancer treatment aligns with market trends favoring early intervention therapies. This positioning could provide AstraZeneca with a competitive edge and sustained revenue growth.
Financial projections would need to be adjusted to account for the potential new indications for IMFINZI, which might positively affect earnings and stock valuation in the medium to long term.
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Approximately one in four patients with bladder cancer has evidence of the tumor invading the muscle wall of the bladder (without distant metastases), known as MIBC.1,2 In the MIBC setting, approximately 117,000 patients are treated with current standard of care.3 Standard treatment includes neoadjuvant chemotherapy and radical cystectomy.4 However, even after cystectomy, patients experience high rates of recurrence and a poor prognosis.4
Professor Thomas Powles, MD, Professor, Director of Barts Cancer Centre (QMUL),
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “The NIAGARA results support our strategy to move immunotherapy to the early stages of cancer treatment. This perioperative regimen with IMFINZI improved survival and reduced the rate at which patients experience disease recurrence or progression. We are eager to bring this regimen with the potential to transform the standard of care to patients as soon as possible.”
IMFINZI was generally well-tolerated and no new safety concerns were observed in either the neoadjuvant or adjuvant setting. The safety profile of IMFINZI and neoadjuvant chemotherapy was consistent with the known profile of the individual medicines. The addition of IMFINZI did not increase the discontinuation rate due to adverse events and did not compromise patients' ability to complete surgery compared to neoadjuvant chemotherapy alone. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
IMPORTANT SAFETY INFORMATION
There are no contraindications for IMFINZI® (durvalumab) or IMJUDO® (tremelimumab-actl).
Severe and Fatal Immune-Mediated Adverse Reactions
Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment or after discontinuation. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue IMFINZI and IMJUDO depending on severity. See USPI Dosing and Administration for specific details. In general, if IMFINZI and IMJUDO requires interruption or discontinuation, administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
Immune-Mediated Pneumonitis
IMFINZI and IMJUDO can cause immune-mediated pneumonitis, which may be fatal. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.
-
IMFINZI as a Single Agent
-
In patients who did not receive recent prior radiation, the incidence of immune-mediated pneumonitis was
2.4% (34/1414), including fatal (<0.1% ), and Grade 3-4 (0.4% ) adverse reactions. In patients who received recent prior radiation, the incidence of pneumonitis (including radiation pneumonitis) in patients with unresectable Stage III NSCLC following definitive chemoradiation within 42 days prior to initiation of IMFINZI in PACIFIC was18.3% (87/475) in patients receiving IMFINZI and12.8% (30/234) in patients receiving placebo. Of the patients who received IMFINZI (475),1.1% were fatal and2.7% were Grade 3 adverse reactions. - The frequency and severity of immune-mediated pneumonitis in patients who did not receive definitive chemoradiation prior to IMFINZI were similar in patients who received IMFINZI as a single agent or with ES-SCLC or BTC when given in combination with chemotherapy.
-
In patients who did not receive recent prior radiation, the incidence of immune-mediated pneumonitis was
-
IMFINZI with IMJUDO
-
Immune‑mediated pneumonitis occurred in
1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3% ) and Grade 3 (0.2% ) adverse reactions.
-
Immune‑mediated pneumonitis occurred in
- IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated pneumonitis occurred in
3.5% (21/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including fatal (0.5% ), and Grade 3 (1% ) adverse reactions.
Immune-Mediated Colitis
IMFINZI with IMJUDO and platinum-based chemotherapy can cause immune-mediated colitis, which may be fatal.
IMFINZI and IMJUDO can cause immune-mediated colitis that is frequently associated with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.
-
IMFINZI as a Single Agent
-
Immune-mediated colitis occurred in
2% (37/1889) of patients receiving IMFINZI, including Grade 4 (<0.1% ) and Grade 3 (0.4% ) adverse reactions.
-
Immune-mediated colitis occurred in
-
IMFINZI with IMJUDO
-
Immune‑mediated colitis or diarrhea occurred in
6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6% ) adverse reactions. Intestinal perforation has been observed in other studies of IMFINZI and IMJUDO.
-
Immune‑mediated colitis or diarrhea occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated colitis occurred in
6.5% (39/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy including fatal (0.2% ) and Grade 3 (2.5% ) adverse reactions. Intestinal perforation and large intestine perforation were reported in0.1% of patients.
-
Immune-mediated colitis occurred in
Immune-Mediated Hepatitis
IMFINZI and IMJUDO can cause immune-mediated hepatitis, which may be fatal.
-
IMFINZI as a Single Agent
-
Immune-mediated hepatitis occurred in
2.8% (52/1889) of patients receiving IMFINZI, including fatal (0.2% ), Grade 4 (0.3% ) and Grade 3 (1.4% ) adverse reactions.
-
Immune-mediated hepatitis occurred in
-
IMFINZI with IMJUDO
-
Immune‑mediated hepatitis occurred in
7.5% (29/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.8% ), Grade 4 (0.3% ) and Grade 3 (4.1% ) adverse reactions.
-
Immune‑mediated hepatitis occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated hepatitis occurred in
3.9% (23/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including fatal (0.3% ), Grade 4 (0.5% ), and Grade 3 (2% ) adverse reactions.
-
Immune-mediated hepatitis occurred in
Immune-Mediated Endocrinopathies
-
Adrenal Insufficiency: IMFINZI and IMJUDO can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated.
-
IMFINZI as a Single Agent
-
Immune-mediated adrenal insufficiency occurred in
0.5% (9/1889) of patients receiving IMFINZI, including Grade 3 (<0.1% ) adverse reactions.
-
Immune-mediated adrenal insufficiency occurred in
-
IMFINZI with IMJUDO
-
Immune-mediated adrenal insufficiency occurred in
1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3% ) adverse reactions.
-
Immune-mediated adrenal insufficiency occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated adrenal insufficiency occurred in
2.2% (13/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.8% ) adverse reactions.
-
Immune-mediated adrenal insufficiency occurred in
-
IMFINZI as a Single Agent
-
Hypophysitis: IMFINZI and IMJUDO can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate symptomatic treatment including hormone replacement as clinically indicated.
-
IMFINZI as a Single Agent
-
Grade 3 hypophysitis/hypopituitarism occurred in <
0.1% (1/1889) of patients who received IMFINZI.
-
Grade 3 hypophysitis/hypopituitarism occurred in <
-
IMFINZI with IMJUDO
-
Immune-mediated hypophysitis/hypopituitarism occurred in
1% (4/388) of patients receiving IMFINZI and IMJUDO.
-
Immune-mediated hypophysitis/hypopituitarism occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated hypophysitis occurred in
1.3% (8/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.5% ) adverse reactions.
-
Immune-mediated hypophysitis occurred in
-
IMFINZI as a Single Agent
-
Thyroid Disorders (Thyroiditis, Hyperthyroidism, and Hypothyroidism): IMFINZI and IMJUDO can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement therapy for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated.
-
IMFINZI as a Single Agent
-
Immune-mediated thyroiditis occurred in
0.5% (9/1889) of patients receiving IMFINZI, including Grade 3 (<0.1% ) adverse reactions. -
Immune-mediated hyperthyroidism occurred in
2.1% (39/1889) of patients receiving IMFINZI. -
Immune-mediated hypothyroidism occurred in
8.3% (156/1889) of patients receiving IMFINZI, including Grade 3 (<0.1% ) adverse reactions.
-
Immune-mediated thyroiditis occurred in
-
IMFINZI with IMJUDO
-
Immune-mediated thyroiditis occurred in
1.5% (6/388) of patients receiving IMFINZI and IMJUDO. -
Immune-mediated hyperthyroidism occurred in
4.6% (18/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3% ) adverse reactions. -
Immune-mediated hypothyroidism occurred in
11% (42/388) of patients receiving IMFINZI and IMJUDO.
-
Immune-mediated thyroiditis occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated thyroiditis occurred in
1.2% (7/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy. -
Immune-mediated hyperthyroidism occurred in
5% (30/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.2% ) adverse reactions. -
Immune-mediated hypothyroidism occurred in
8.6% (51/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.5% ) adverse reactions.
-
Immune-mediated thyroiditis occurred in
-
IMFINZI with Carboplatin and Paclitaxel
-
Immune-mediated hypothyroidism occurred in
14% (34/235) of patients receiving IMFINZI in combination with carboplatin and paclitaxel.
-
Immune-mediated hypothyroidism occurred in
-
IMFINZI as a Single Agent
-
Type 1 Diabetes Mellitus, which can present with diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated.
-
IMFINZI as a Single Agent
-
Grade 3 immune-mediated Type 1 diabetes mellitus occurred in <
0.1% (1/1889) of patients receiving IMFINZI.
-
Grade 3 immune-mediated Type 1 diabetes mellitus occurred in <
-
IMFINZI with IMJUDO
-
Two patients (
0.5% , 2/388) had events of hyperglycemia requiring insulin therapy that had not resolved at last follow-up.
-
Two patients (
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated Type 1 diabetes mellitus occurred in
0.5% (3/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy including Grade 3 (0.3% ) adverse reactions.
-
Immune-mediated Type 1 diabetes mellitus occurred in
-
IMFINZI as a Single Agent
Immune-Mediated Nephritis with Renal Dysfunction
IMFINZI and IMJUDO can cause immune-mediated nephritis.
-
IMFINZI as a Single Agent
-
Immune-mediated nephritis occurred in
0.5% (10/1889) of patients receiving IMFINZI, including Grade 3 (<0.1% ) adverse reactions.
-
Immune-mediated nephritis occurred in
-
IMFINZI with IMJUDO
-
Immune-mediated nephritis occurred in
1% (4/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.5% ) adverse reactions.
-
Immune-mediated nephritis occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated nephritis occurred in
0.7% (4/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.2% ) adverse reactions.
-
Immune-mediated nephritis occurred in
Immune-Mediated Dermatology Reactions
IMFINZI and IMJUDO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/L-1 and CTLA-4 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes.
-
IMFINZI as a Single Agent
-
Immune-mediated rash or dermatitis occurred in
1.8% (34/1889) of patients receiving IMFINZI, including Grade 3 (0.4% ) adverse reactions.
-
Immune-mediated rash or dermatitis occurred in
-
IMFINZI with IMJUDO
-
Immune-mediated rash or dermatitis occurred in
4.9% (19/388) of patients receiving IMFINZI and IMJUDO, including Grade 4 (0.3% ) and Grade 3 (1.5% ) adverse reactions.
-
Immune-mediated rash or dermatitis occurred in
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Immune-mediated rash or dermatitis occurred in
7.2% (43/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.3% ) adverse reactions.
-
Immune-mediated rash or dermatitis occurred in
Immune-Mediated Pancreatitis
IMFINZI in combination with IMJUDO can cause immune-mediated pancreatitis. Immune-mediated pancreatitis occurred in
Other Immune-Mediated Adverse Reactions
The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than
- Cardiac/vascular: Myocarditis, pericarditis, vasculitis.
- Nervous system: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy.
- Ocular: Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.
- Gastrointestinal: Pancreatitis including increases in serum amylase and lipase levels, gastritis, duodenitis.
- Musculoskeletal and connective tissue disorders: Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic.
- Endocrine: Hypoparathyroidism.
- Other (hematologic/immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection.
Infusion-Related Reactions
IMFINZI and IMJUDO can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue IMFINZI and IMJUDO based on the severity. See USPI Dosing and Administration for specific details. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses.
-
IMFINZI as a Single Agent
-
Infusion-related reactions occurred in
2.2% (42/1889) of patients receiving IMFINZI, including Grade 3 (0.3% ) adverse reactions.
-
Infusion-related reactions occurred in
-
IMFINZI with IMJUDO
-
Infusion-related reactions occurred in 10 (
2.6% ) patients receiving IMFINZI and IMJUDO.
-
Infusion-related reactions occurred in 10 (
-
IMFINZI with IMJUDO and Platinum-Based Chemotherapy
-
Infusion-related reactions occurred in
2.9% (17/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.3% ) adverse reactions.
-
Infusion-related reactions occurred in
Complications of Allogeneic HSCT after IMFINZI
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/L-1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/L-1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/L-1 blocking antibody prior to or after an allogeneic HSCT.
Embryo-Fetal Toxicity
Based on their mechanism of action and data from animal studies, IMFINZI and IMJUDO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and IMJUDO and advise them to use effective contraception during treatment with IMFINZI and IMJUDO and for 3 months after the last dose of IMFINZI and IMJUDO.
Lactation
There is no information regarding the presence of IMFINZI and IMJUDO in human milk; however, because of the potential for serious adverse reactions in breastfed infants from IMFINZI and IMJUDO, advise women not to breastfeed during treatment and for 3 months after the last dose.
Adverse Reactions
-
In patients with Stage III NSCLC in the PACIFIC study receiving IMFINZI (n=475), the most common adverse reactions (≥
20% ) were cough (40% ), fatigue (34% ), pneumonitis or radiation pneumonitis (34% ), upper respiratory tract infections (26% ), dyspnea (25% ), and rash (23% ). The most common Grade 3 or 4 adverse reactions (≥3% ) were pneumonia (7% ) and pneumonitis/radiation pneumonitis (3.4% ). -
In patients with Stage III NSCLC in the PACIFIC study receiving IMFINZI (n=475), discontinuation due to adverse reactions occurred in
15% of patients in the IMFINZI arm. Serious adverse reactions occurred in29% of patients receiving IMFINZI. The most frequent serious adverse reactions (≥2% ) were pneumonitis or radiation pneumonitis (7% ) and pneumonia (6% ). Fatal pneumonitis or radiation pneumonitis and fatal pneumonia occurred in <2% of patients and were similar across arms. -
In patients with mNSCLC in the POSEIDON study receiving IMFINZI and IMJUDO plus platinum-based chemotherapy (n=330), the most common adverse reactions (occurring in ≥
20% of patients) were nausea (42% ), fatigue (36% ), musculoskeletal pain (29% ), decreased appetite (28% ), rash (27% ), and diarrhea (22% ). -
In patients with mNSCLC in the POSEIDON study receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy (n=330), permanent discontinuation of IMFINZI or IMJUDO due to an adverse reaction occurred in
17% of patients. Serious adverse reactions occurred in44% of patients, with the most frequent serious adverse reactions reported in at least2% of patients being pneumonia (11% ), anemia (5% ), diarrhea (2.4% ), thrombocytopenia (2.4% ), pyrexia (2.4% ), and febrile neutropenia (2.1% ). Fatal adverse reactions occurred in a total of4.2% of patients. -
In patients with extensive-stage SCLC in the
CASPIAN study receiving IMFINZI plus chemotherapy (n=265), the most common adverse reactions (≥20% ) were nausea (34% ), fatigue/asthenia (32% ), and alopecia (31% ). The most common Grade 3 or 4 adverse reaction (≥3% ) was fatigue/asthenia (3.4% ). -
In patients with extensive-stage SCLC in the
CASPIAN study receiving IMFINZI plus chemotherapy (n=265), IMFINZI was discontinued due to adverse reactions in7% of the patients receiving IMFINZI plus chemotherapy. Serious adverse reactions occurred in31% of patients receiving IMFINZI plus chemotherapy. The most frequent serious adverse reactions reported in at least1% of patients were febrile neutropenia (4.5% ), pneumonia (2.3% ), anemia (1.9% ), pancytopenia (1.5% ), pneumonitis (1.1% ), and COPD (1.1% ). Fatal adverse reactions occurred in4.9% of patients receiving IMFINZI plus chemotherapy. -
In patients with locally advanced or metastatic BTC in the TOPAZ-1 study receiving IMFINZI (n=338), the most common adverse reactions (occurring in ≥
20% of patients) were fatigue (42% ), nausea (40% ), constipation (32% ), decreased appetite (26% ), abdominal pain (24% ), rash (23% ), and pyrexia (20% ). -
In patients with locally advanced or metastatic BTC in the TOPAZ-1 study receiving IMFINZI (n=338), discontinuation due to adverse reactions occurred in
6% of the patients receiving IMFINZI plus chemotherapy. Serious adverse reactions occurred in47% of patients receiving IMFINZI plus chemotherapy. The most frequent serious adverse reactions reported in at least2% of patients were cholangitis (7% ), pyrexia (3.8% ), anemia (3.6% ), sepsis (3.3% ) and acute kidney injury (2.4% ). Fatal adverse reactions occurred in3.6% of patients receiving IMFINZI plus chemotherapy. These include ischemic or hemorrhagic stroke (4 patients), sepsis (2 patients), and upper gastrointestinal hemorrhage (2 patients). -
In patients with unresectable HCC in the HIMALAYA study receiving IMFINZI and IMJUDO (n=388), the most common adverse reactions (occurring in ≥
20% of patients) were rash (32% ), diarrhea (27% ), fatigue (26% ), pruritus (23% ), musculoskeletal pain (22% ), and abdominal pain (20% ). -
In patients with unresectable HCC in the HIMALAYA study receiving IMFINZI and IMJUDO (n=388), serious adverse reactions occurred in
41% of patients. Serious adverse reactions in >1% of patients included hemorrhage (6% ), diarrhea (4% ), sepsis (2.1% ), pneumonia (2.1% ), rash (1.5% ), vomiting (1.3% ), acute kidney injury (1.3% ), and anemia (1.3% ). Fatal adverse reactions occurred in8% of patients who received IMFINZI and IMJUDO, including death (1% ), hemorrhage intracranial (0.5% ), cardiac arrest (0.5% ), pneumonitis (0.5% ), hepatic failure (0.5% ), and immune-mediated hepatitis (0.5% ). Permanent discontinuation of treatment regimen due to an adverse reaction occurred in14% of patients. -
In patients with advanced or recurrent dMMR endometrial cancer in the DUO-E study receiving IMFINZI in combination with carboplatin and paclitaxel followed by IMFINZI as a single-agent (n=44), the most common adverse reactions, including laboratory abnormalities (occurring in >
20% of patients) were peripheral neuropathy (61% ), musculoskeletal pain (59% ), nausea (59% ), alopecia (52% ), fatigue (41% ), abdominal pain (39% ), constipation (39% ), rash (39% ), decreased magnesium (36% ), increased ALT (32% ), increased AST (30% ), diarrhea (27% ), vomiting (27% ), cough (27% ), decreased potassium (25% ), dyspnea (25% ), headache (23% ), increased alkaline phosphatase (20% ), and decreased appetite (18% ). The most common Grade 3 or 4 adverse reactions (≥3% ) were constipation (4.5% ) and fatigue (4.5% ). -
In patients with advanced or recurrent dMMR endometrial cancer in the DUO-E study receiving IMFINZI in combination with carboplatin and paclitaxel followed by IMFINZI as a single-agent (n=44), permanent discontinuation of IMFINZI due to adverse reactions occurred in
11% of patients. Serious adverse reactions occurred in30% of patients who received IMFINZI with carboplatin and paclitaxel; the most common serious adverse reactions (≥4% ) were constipation (4.5% ) and rash (4.5% ).
The safety and effectiveness of IMFINZI and IMJUDO have not been established in pediatric patients.
Indications:
IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
IMFINZI, in combination with IMJUDO and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
IMFINZI in combination with IMJUDO is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
IMFINZI in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
Please see additional Important Safety Information throughout and Full Prescribing Information including Medication Guide for IMFINZI and IMJUDO.
You may report side effects related to AstraZeneca products (opens new window).
Notes
Muscle-invasive bladder cancer
Bladder cancer is the 9th most common cancer in the world, with more than 614,000 patients diagnosed each year.5 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract.6
Muscle-invasive bladder cancer, named for its growth into the muscle wall of the bladder, accounts for about a quarter of all bladder cancer cases.1,2 Approximately
NIAGARA
NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating IMFINZI as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1063 patients were randomised to receive IMFINZI plus chemotherapy or chemotherapy alone prior to cystectomy, followed by IMFINZI or no further treatment after surgery.
The trial is being conducted at 192 centers across 22 countries and regions including in
IMFINZI
IMFINZI® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading tactics and releasing the inhibition of immune responses.
IMFINZI is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiation therapy. IMFINZI is also approved for the treatment of extensive-stage small cell lung cancer (SCLC) and in combination with a short course of IMJUDO® (tremelimumab) and chemotherapy for the treatment of metastatic NSCLC.
IMFINZI in combination with neoadjuvant platinum-containing chemotherapy before surgery and as adjuvant monotherapy after surgery has been approved in
In addition to its indications in lung cancers, IMFINZI is approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer and in combination with IMJUDO in unresectable hepatocellular carcinoma (HCC). IMFINZI is also approved as a monotherapy in unresectable HCC in
Since the first approval in May 2017, more than 220,000 patients have been treated with IMFINZI. As part of a broad development program, IMFINZI is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, breast cancer, several gastrointestinal and gynecologic cancers, and other solid tumors.
IMFINZI is being tested across early- and late-stage bladder cancer in various treatment combinations, including in non-muscle invasive disease (POTOMAC), patients with MIBC who are cisplatin-ineligible or refusing cisplatin (VOLGA) and locally advanced or metastatic disease (NILE).
AstraZeneca in immuno-oncology (IO)
AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumor immune response and stimulate the body’s immune system to attack tumors.
AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies as well as therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T cell engagers.
AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. With an extensive clinical program, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in
References | |||||
1. |
Burger M, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur Urol. 2013;63(2):234-241. |
||||
2. |
National Collaborating Centre for Cancer. Bladder Cancer: Diagnosis and Management. |
||||
3. |
Cerner CancerMPact database. Accessed June 2024. Reflects epidemiology estimates across G8 countries (US, EU, |
||||
4. |
Witjes JA, et al. EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2021;1-94. |
||||
5. |
World Health Organization. International Agency for Research on Cancer. Bladder Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf. Accessed June 2024. |
||||
6. |
American Cancer Society. What Is Bladder Cancer? Available at: https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html. Accessed June 2024. |
US-91093 Last Updated 6/24
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625461835/en/
Media Inquiries
Brendan McEvoy +1 302 885 2677
Chelsea Tressler +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
Source: AstraZeneca
FAQ
What does the NIAGARA Phase III trial reveal about IMFINZI (AZN) for muscle-invasive bladder cancer?
How does IMFINZI (AZN) affect survival rates for muscle-invasive bladder cancer?
What are the safety concerns associated with IMFINZI (AZN) in the treatment of muscle-invasive bladder cancer?
How does IMFINZI (AZN) compare to standard neoadjuvant chemotherapy for muscle-invasive bladder cancer?